Schizosaccharomyces pombe Fzo1 is subjected to the ubiquitin-proteasome-mediated degradation during the stationary phase

Staphylococcus epidermidis biofilm in inflammatory breast cancer and its treatment strategies

Bacterial biofilms represent a significant challenge in both clinical and industrial settings because of their robust nature and resistance to antimicrobials. Biofilms are formed by microorganisms that produce an exopolysaccharide matrix, protecting function and supporting for nutrients. Among the various bacterial species capable of forming biofilms, Staphylococcus epidermidis, a commensal organism found on human skin and mucous membranes, has emerged as a prominent opportunistic pathogen, when introduced into the body via medical devices, such as catheters, prosthetic joints, and heart valves. The formation of biofilms by S. epidermidis on these surfaces facilitates colonization and provides protection against host immune responses and antibiotic therapies, leading to persistent and difficult-to-treat infections. The possible involvement of biofilms for breast oncogenesis has recently created the curiosity. This paper therefore delves into S. epidermidis biofilm involvement in breast cancer. S. epidermidis biofilms can create a sustained inflammatory environment through their metabolites and can break DNA in breast tissue, promoting cellular proliferation, angiogenesis, and genetic instability. Preventing biofilm formation primarily involves preventing bacterial proliferation using prophylactic measures and sterilization of medical devices and equipment. In cancer treatment, common modalities include chemotherapy, surgery, immunotherapy, alkylating agents, and various anticancer drugs. Understanding the relationship between anticancer drugs and bacterial biofilms is crucial, especially for those undergoing cancer treatment who may be at increased risk of bacterial infections, for improving patient outcomes. By elucidating these interactions, strategies to prevent or disrupt biofilm formation, thereby reducing the incidence of infections associated with medical devices and implants, can be identified.

Schizosaccharomyces pombe MAP kinase Sty1 promotes survival of Δppr10 cells with defective mitochondrial protein synthesis

Deletion of the Schizosaccharomyces pombe pentatricopeptide repeat gene ppr10 severely impairs mitochondrial translation, resulting in defective oxidative phosphorylation (OXPHOS). ppr10 deletion also induces iron starvation response, resulting in increased reactive oxygen species (ROS) production and reduced viability under fermentative conditions. S. pombe has two principal stress-response pathways, which are mediated by the mitogen-activated protein kinase Sty1 and the basic leucine zipper transcription factor Pap1, respectively. In this study, we examined the roles of Sty1 and Pap1 in the cellular response to the mitochondrial translation defect caused by ppr10 deletion. We found that ppr10 deletion resulted in two waves of stress protein activation. The early response occurred in exponential phase and resulted in the expression of a subset of stress proteins including Gst2 and Obr1. The upregulation of some of these stress proteins in Δppr10 cells in early response is dependent on the basal nuclear levels of Sty1 or Pap1. The late response occurred in early stationary phase and coincided with the stable localization of Sty1 and Pap1 in the nucleus, presumably resulting in persistent activation of a large set of stress proteins. Deletion of sty1 in Δppr10 cells caused severe defects in cell division and growth, and further impaired cell viability. Deletion of the mitochondrial superoxide dismutase gene sod2 whose expression is controlled by Sty1 severely inhibited the growth of Δppr10 cells. Overexpression of sod2 improves the viability of Δppr10 cells. Our results support an important role for Sty1 in counteracting stress induced by ppr10 deletion under fermentative growth conditions.